<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR19">
 <label>19.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Hammers</surname>
    <given-names>HJ</given-names>
   </name>
   <name>
    <surname>Plimack</surname>
    <given-names>ER</given-names>
   </name>
   <name>
    <surname>Infante</surname>
    <given-names>JR</given-names>
   </name>
   <name>
    <surname>Rini</surname>
    <given-names>BI</given-names>
   </name>
   <name>
    <surname>McDermott</surname>
    <given-names>DF</given-names>
   </name>
   <name>
    <surname>Lewis</surname>
    <given-names>LD</given-names>
   </name>
   <name>
    <surname>Voss</surname>
    <given-names>MH</given-names>
   </name>
   <name>
    <surname>Sharma</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Pal</surname>
    <given-names>SK</given-names>
   </name>
   <name>
    <surname>Razak</surname>
    <given-names>ARA</given-names>
   </name>
   <name>
    <surname>Kollmannsberger</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Heng</surname>
    <given-names>DYC</given-names>
   </name>
   <name>
    <surname>Spratlin</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>McHenry</surname>
    <given-names>MB</given-names>
   </name>
   <name>
    <surname>Amin</surname>
    <given-names>A</given-names>
   </name>
  </person-group>
  <article-title>Safety and efficacy of Nivolumab in combination with Ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study</article-title>
  <source>J Clin Oncol</source>
  <year>2017</year>
  <volume>35</volume>
  <issue>34</issue>
  <fpage>3851</fpage>
  <lpage>3858</lpage>
  <pub-id pub-id-type="doi">10.1200/JCO.2016.72.1985</pub-id>
  <?supplied-pmid 28678668?>
  <pub-id pub-id-type="pmid">28678668</pub-id>
 </element-citation>
</ref>
